Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line

Biochemical Pharmacology

Volumn 65, Issue 7, 2003, Pages 1163-1170

  Wang, Yanhua ^a   Zhao, Rongboa ^a   Goldman, I David ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Alimta; Antifolate resistance; Antifolates; Multi targeted antifolate; Pemetrexed

Indexed keywords

ANTINEOPLASTIC AGENT; CARRIER PROTEIN; DNA; FOLATE RECEPTOR; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; FOLYPOLYGLUTAMATE SYNTHETASE; LOMOTREXOL; MESSENGER RNA; METHOTREXATE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PLEVITREXED; POLYGLUTAMIC ACID; RALTITREXED; RECEPTOR; SYNTHETASE; TETRAHYDROFOLIC ACID DERIVATIVE; THYMIDYLATE SYNTHASE; TRIMETREXATE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER RESISTANCE; CELL GROWTH; CHEMICAL MUTAGENESIS; CONTROLLED STUDY; CROSS RESISTANCE; DNA SEQUENCE; DRUG ACCUMULATION; DRUG SENSITIVITY; DRUG UPTAKE; LEUKEMIA CELL LINE; LEUKEMIA L 1210; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM;

ANIMALS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FOLIC ACID; FOLIC ACID ANTAGONISTS; GENE SILENCING; GLUTAMATES; GUANINE; HYDROXYMETHYL AND FORMYL TRANSFERASES; LEUKEMIA L1210; MEMBRANE TRANSPORT PROTEINS; MICE; PEPTIDE SYNTHASES; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; TUMOR CELLS, CULTURED;

EID: 0037377560     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00007-8     Document Type: Article

References (47)

1. Taylor E.C., Kuhnt D., Shih C., Rinzel S.M., Grindey G.B., Barredo J., Jannatipour M., Moran R.G. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl) ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J. Med. Chem. 35:1992;4450-4454.
2. Shih C., Chen V.J., Gossett L.S., Gates S.B., MacKellar W.C., Habeck L.L., Shackelford K.A., Mendelsohn L.G., Soose D.J., Patel V.F., Andis S.L., Bewley J.R., Rayl E.A., Moroson B.A., Beardsley G.P., Kohler W., Ratnam M., Schultz R.M. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 57:1997;1116-1123.
3. Goldman I.D., Matherly L.H. The cellular pharmacology of methotrexate. Pharmacol. Ther. 28:1985;77-102.
4. Seither R.L., Trent D.F., Mikulecky D.C., Rape T.J., Goldman I.D. Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. Experimental and network thermodynamic analyses of the role of dihydrofolate polyglutamylates in antifolate action in cells. J. Biol. Chem. 264:1989;17016-17023.
5. Curtin N.J., Hughes A.N. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol. 2:2001;298-306.
6. Hughes A., Calvert P., Azzabi A., Plummer R., Johnson R., Rusthoven J., Griffin M., Fishwick K., Boddy A.V., Verrill M., Calvert H. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J. Clin. Oncol. 20:2002;3533-3544.
7. Zhao R., Sharina I.G., Goldman I.D. Pattern of mutations that results in loss of reduced folate carrier function under antifolate selective pressure augmented by chemical mutagenesis. Mol. Pharmacol. 56:1999;68-76.
8. Drake J.C., Allegra C.J., Moran R.G., Johnston P.G. Resistance to Tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines. Biochem. Pharmacol. 51:1996;1349-1355.
9. Jackman A.L., Kelland L.R., Kimbell R., Brown M., Gibson W., Aherne G.W., Hardcastle A., Boyle F.T. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br. J. Cancer. 71:1995;914-924.
10. Cowan K.H., Jolivet J. A methotrexate-resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates. J. Biol. Chem. 259:1984;10793-10800.
11. Matherly L.H., Taub J.W., Wong S.C., Simpson P.M., Ekizian R., Buck S., Williamson M., Amylon M., Pullen J., Camitta B., Ravindranath Y. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. Blood. 90:1997;578-589.
12. Matherly L.H. Molecular and cellular biology of the human reduced folate carrier. Prog. Nucleic Acid. Res. Mol. Biol. 67:2001;131-162.
13. Guo W., Healey J.H., Meyers P.A., Ladanyi M., Huvos A.G., Bertino J.R., Gorlick R. Mechanisms of methotrexate resistance in osteosarcoma. Clin. Cancer Res. 5:1999;621-627.
14. Gorlick R., Goker E., Trippett T., Steinherz P., Elisseyeff Y., Mazumdar M., Flintoff W.F., Bertino J.R. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood. 89:1997;1013-1018.
15. Zhang L., Taub J.W., Williamson M., Wong S.C., Hukku B., Pullen J., Ravindranath Y., Matherly L.H. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. Clin. Cancer Res. 4:1998;2169-2177.
16. Yang R., Mazza B., Sowers R., Healey J., Huvos A., Bertino J.R., Meyers P., Gorlick R. Mutations/polymorphisms in the reduced folate carrier (RFC) are frequently in osteosarcoma tumor samples. Proc. Am. Assoc. Cancer Res. 42:2001;921.
17. Zhao R., Assaraf Y.G., Goldman I.D. A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function. J. Biol. Chem. 273:1998;19065-19071.
18. Zhao R., Assaraf Y.G., Goldman I.D. A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate. J. Biol. Chem. 273:1998;7873-7879.
19. Zhao R., Gao F., Babani S., Goldman I.D. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier. Clin. Cancer Res. 6:2000;3304-3311.
20. Van der Wilt C.L., Backus H.H., Smid K., Comijn L., Veerman G., Wouters D., Voorn D.A., Priest D.G., Bunni M.A., Mitchell F., Jackman A.L., Jansen G., Peters G.J. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res. 61:2001;3675-3681.
21. Zhao R., Gao F., Goldman I.D. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem. Pharmacol. 61:2001;857-865.
22. Zhao R., Babani S., Gao F., Liu L., Goldman I.D. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin. Cancer Res. 6:2000;3687-3695.
23. Yang C.-H., Dembo M., Sirotnak F.M. Relationships between carrier-mediated transport of folate compounds by L1210 leukemia cells: evidence for multiplicity of entry routes with different kinetic properties expressed in plasma membrane vesicles. J. Membr. Biol. 75:1983;11-20.
24. Sirotnak F.M., Goutas L.J., Jacobsen D.M., Mines L.S., Barrueco J.R., Gaumont Y., Kisliuk R.L. Carrier-mediated transport of folate compounds in L1210 cells. Biochem. Pharmacol. 36:1987;1659-1667.
25. Fry D.W., Yalowich J.C., Goldman I.D. Rapid formation of poly-γ-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro. J. Biol. Chem. 257:1982;1890-1896.
26. Zhao R., Seither R., Brigle K.E., Sharina I.G., Wang P.J., Goldman I.D. Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells. J. Biol. Chem. 272:1997;21207-21212.
27. Zhao R., Gao F., Liu L., Goldman I.D. The reduced folate carrier in L1210 murine leukemia cells is a 58-kDa protein. Biochim. Biophys. Acta. 1466:2000;7-10.
28. Allegra C.J., Drake J.C., Jolivet J., Chabner B.A. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl. Acad. Sci. U.S.A. 82:1985;4881-4885.
29. Allegra C.J., Chabner B.A., Drake J.C., Lutz R., Rodbard D., Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J. Biol. Chem. 260:1985;9720-9726.
30. Mendelsohn LG, Worzalla JF, Walling JM. Preclinical and clinical evaluation of the glycinamide ribonucleotide formyltransferase inhibitors lometrexol and LY309887. In: Jackman AL, editor. Antifolate drugs in cancer therapy. Totowa, NJ: Humana Press; 1999. p. 261-80.
31. Boritzki TJ, Zhang C, Bartlett CA, Jackson RC. Ag2034, a GARFT inhibitor with selective cytotoxicity to cells that lack a g1 checkpoint. In: Jackman AL, editor. Antifolate drugs in cancer therapy. Totowa, NJ: Humana Press; 1999. p. 281-92.
32. Bisset G.M.F., Pawelczak K., Jackman A.L., Calvert A.H., Hughes L.R. Syntheses and thymidylate synthase inhibitory activity of the poly-γ-glutamyl conjugates of N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2- thenoyl]-L-glutamic acid (ICI D1694) and other quinazoline antifolates. J. Med. Chem. 35:1992;859-866.
33. Ward W.H.J., Kimbell R., Jackman A.L. Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase. Biochem. Pharmacol. 43:1992;2029-2031.
34. Westerhof G.R., Schornagel J.H., Kathmann I., Jackman A.L., Rosowsky A., Forsch R.A., Hynes J.B., Boyle F.T., Peters G.J., Pinedo H.M., Jansen G. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol. Pharmacol. 48:1995;459-471.
35. Habeck L.L., Mendelsohn L.G., Shih C., Taylor E.C., Colman P.D., Gossett L.S., Leitner T.A., Schultz R.M., Andis S.L., Moran R.G. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. Mol. Pharmacol. 48:1995;326-333.
36. Schultz R.M., Chen V.J., Bewley J.R., Roberts E.F., Shih C., Dempsey J.A. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin. Oncol. 26:1999;68-73.
37. Tse A., Moran R.G. Cellular folates prevent polyglutamation of 5,10-dideazatetrahydrofolate. A novel mechanism of resistance to folate antimetabolites. J. Biol. Chem. 273:1998;25944-25952.
38. Tse A., Brigle K., Taylor S.M., Moran R.G. Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate. J. Biol. Chem. 273:1998;25953-25960.
39. Assaraf Y.G., Goldman I.D. Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells. J. Biol. Chem. 272:1997;17460-17466.
40. Jansen G., Barr H., Kathmann I., Bunni M.A., Priest D.G., Noordhuis P., Peters G.J., Assaraf Y.G. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol. Pharmacol. 55:1999;761-769.
41. Goldman I.D., Lichtenstein N.S., Oliverio V.T. Carrier-mediated transport of the folic acid analogue methotrexate, in the L1210 leukemia cell. J. Biol. Chem. 243:1968;5007-5017.
42. Brigle K.E., Spinella M.J., Sierra E.E., Goldman I.D. Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. J. Biol. Chem. 270:1995;22974-22979.
43. Zhao R., Titus S., Gao F., Moran R.G., Goldman I.D. Molecular analysis of murine leukemia cell lines resistant to 5,10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. J. Biol. Chem. 275:2000;26599-26606.
44. Rhee M.S., Ryan T.J., Galivan J. Glutamyl hydrolase and the multitargeted antifolate LY231514. Cancer Chemother. Pharmacol. 44:1999;427-432.
45. McGuire J.J., Russell C.A. Folylpolyglutamate synthetase expression in antifolate-sensitive and-resistant human cell lines. Oncol. Res. 10:1998;193-200.
46. McGuire J.J., Haile W.H., Russell C.A., Galvin J.M., Shane B. Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure. Oncol. Res. 7:1995;535-543.
47. Jackman A.L., Kimbell R., Aherne G.W., Brunton L., Jansen G., Stephens T.C., Smith M.N., Wardleworth J.M., Boyle F.T. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin. Cancer Res. 3:1997;911-921.